Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
186.16
+0.99 (0.53%)
Jan 29, 2026, 9:51 AM EST - Market open
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 21 analysts that cover Axsome Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $193.19, which forecasts a 3.78% increase in the stock price over the next year. The lowest target is $143 and the highest is $260.
Price Target: $193.19 (+3.78%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 9 | 9 | 9 |
| Buy | 10 | 11 | 11 | 11 | 11 | 11 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 18 | 19 | 20 | 20 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $150 → $205 | Buy | Maintains | $150 → $205 | +10.12% | Jan 28, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $212 → $219 | Buy | Maintains | $212 → $219 | +17.64% | Jan 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $200 → $260 | Strong Buy | Maintains | $200 → $260 | +39.66% | Jan 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $148 → $223 | Buy | Maintains | $148 → $223 | +19.79% | Jan 16, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $157 → $193 | Buy | Maintains | $157 → $193 | +3.67% | Jan 13, 2026 |
Financial Forecast
Revenue This Year
645.76M
from 385.69M
Increased by 67.43%
Revenue Next Year
1.02B
from 645.76M
Increased by 58.11%
EPS This Year
-3.72
from -5.99
EPS Next Year
0.82
from -3.72
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 675.1M | 1.3B | ||||
| Avg | 645.8M | 1.0B | ||||
| Low | 611.8M | 819.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 75.0% | 106.1% | ||||
| Avg | 67.4% | 58.1% | ||||
| Low | 58.6% | 27.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.25 | 5.24 | ||||
| Avg | -3.72 | 0.82 | ||||
| Low | -4.02 | -1.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.